(Q35828697)

10 August 2017

Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies (English)

1 reference

Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies

10 August 2017

corrigendum / erratum

0 references

21

Razelle Kurzrock

1 reference

10 August 2017

20

Funda Meric-Bernstam

1 reference

10 August 2017

Apostolia Maria Tsimberidou

3

object named as

Apostolia M Tsimberidou

1 reference

10 August 2017

5

Aung Naing

1 reference

10 August 2017

1

Filip Janku

1 reference

10 August 2017

Philipp Angenendt

2

1 reference

10 August 2017

Siqing Fu

4

1 reference

10 August 2017

Gerald S Falchook

6

1 reference

10 August 2017

David S Hong

7

1 reference

10 August 2017

Veronica R Holley

8

1 reference

10 August 2017

Goran Cabrilo

9

1 reference

10 August 2017

Jennifer J Wheler

10

1 reference

10 August 2017

Sarina A Piha-Paul

11

1 reference

10 August 2017

Ralph G Zinner

12

1 reference

10 August 2017

Agop Y Bedikian

13

1 reference

10 August 2017

Michael J Overman

14

1 reference

10 August 2017

Bryan K Kee

15

1 reference

10 August 2017

Kevin B Kim

16

1 reference

10 August 2017

E Scott Kopetz

17

1 reference

10 August 2017

Rajyalakshmi Luthra

18

1 reference

10 August 2017

Frank Diehl

19

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 May 2015

1 reference

10 August 2017

1 reference

10 August 2017

6

1 reference

10 August 2017

12809-12821

1 reference

10 August 2017

14

1 reference

Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

Concordance of genomic alterations between primary and recurrent breast cancer.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

Detection of circulating tumor DNA in early- and late-stage human malignancies

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

Circulating mutant DNA to assess tumor dynamics

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

Screening for epidermal growth factor receptor mutations in lung cancer

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

Prospective validation of a prognostic score to improve patient selection for oncology phase I trials

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4494976

Uncommon tumors and exceptional therapies: paradox or paradigm?

24 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25980577

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Genetic heterogeneity and cancer drug resistance

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25980577

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.18632/ONCOTARGET.3373

0 references

1 reference

10 August 2017

1 reference